Risk Assessment of Clinically Relevant Incidental Findings Across Repeated Imaging Pathways

Abstract

This review article critically evaluates the risk assessment of clinically relevant incidental findings (IFs) encountered in repeated imaging pathways, synthesizing recent PubMed literature to inform best practices for healthcare professionals. The article examines epidemiology, pathophysiology, risk factors, clinical implications, diagnostic strategies, management, evolving guidelines, and emerging therapeutic approaches. Emphasis is placed on mechanism-based explanations, clinical relevance, and practical guidance for optimizing patient care while mitigating unnecessary interventions.

Introduction

Advancements in imaging technology and the increasing utilization of repeated diagnostic imaging for monitoring disease progression, screening, and surveillance have led to a significant rise in the detection of incidental findings (IFs). These unexpected, asymptomatic findings unrelated to the original imaging indication pose unique clinical challenges. Accurately assessing the risk of IFs is critical to avoid patient harm from over-investigation or under-recognition of clinically significant pathology. This review aims to provide clinicians with a synthesis of current evidence, mechanisms, and guidelines for risk stratification and management of IFs in repeated imaging scenarios.

Epidemiology / Disease Burden

The prevalence of incidental findings varies according to imaging modality, patient population, and anatomical region. Studies report IFs in up to 38% of computed tomography (CT) scans, 24% of magnetic resonance imaging (MRI) studies, and 7% of ultrasonography exams. The frequency of clinically significant IFs, defined as findings that may require medical intervention or surveillance, is considerably lower, estimated at 1.5–6% depending on modality and context. Repeated imaging, such as in oncology follow-up or chronic disease surveillance, amplifies cumulative exposure to IFs. As imaging utilization increases worldwide, the burden of IFs has become a substantial issue for radiologists and referring clinicians, with implications for patient anxiety, resource utilization, and healthcare costs.

Pathophysiology

Incidental findings arise from the detection of anatomical or physiological abnormalities not related to the patient's presenting complaint. These may include benign lesions (e.g., simple cysts), indeterminate masses, or early-stage malignancies. The pathophysiology often reflects age-related changes, subclinical disease, or physiological variants. Mechanistically, repeated imaging increases the likelihood of uncovering new or evolving IFs, some of which may represent true pathology, while others are false positives or innocuous variants. The challenge lies in distinguishing findings that warrant further work-up from those that do not, necessitating a nuanced understanding of disease natural history, imaging artifact, and incidentaloma biology.

Risk Factors

Risk factors for the occurrence of clinically relevant IFs include advanced age, comorbidities (e.g., history of cancer, chronic inflammatory diseases), genetic predispositions, and the use of high-resolution or contrast-enhanced imaging modalities. The anatomical region imaged, frequency of imaging, and patient demographics (such as smoking status or family history) also influence the probability and significance of IFs. Repeated imaging in populations undergoing cancer surveillance or those with hereditary syndromes (such as BRCA mutations) is associated with higher rates of actionable IFs. Additionally, technical factors, such as scan parameters and radiologist expertise, affect detection rates and interpretation.

Clinical Features

By definition, most IFs are asymptomatic at the time of detection. Clinical relevance is determined by the potential of the finding to impact morbidity or mortality if left untreated. Examples include lung nodules detected on serial chest CTs, adrenal incidentalomas on abdominal imaging, and incidental cerebral aneurysms on brain MRI. Features suggestive of higher clinical significance include lesion size, growth over time, irregular margins, and enhancement patterns. The context of the patient's history, previous imaging, and comorbidities further guide the risk stratification process.

Diagnosis

Diagnostic evaluation of IFs should be systematic and evidence-based, balancing the risks of missed significant pathology against those of over-investigation. Key steps include comparison with prior imaging, assessment of growth kinetics, application of validated risk calculators (e.g., Fleischner Society guidelines for lung nodules), and multidisciplinary case review where appropriate. Advanced imaging techniques, such as diffusion-weighted MRI or PET/CT, may aid in characterization. Biopsy or follow-up imaging is reserved for findings with indeterminate or suspicious features after initial assessment. Shared decision-making, patient education, and informed consent are critical, particularly when surveillance or invasive testing is considered.

Treatment & Management

Management strategies for IFs depend on risk stratification and guideline recommendations. Benign or low-risk findings typically require no intervention and may only necessitate documentation in the medical record. Intermediate-risk findings may warrant serial imaging to assess for interval change, while high-risk or suspicious findings prompt further diagnostic work-up or specialist referral. The psychological impact of incidental findings on patients should not be underestimated; clear communication and counseling are essential. Overtreatment, including unnecessary biopsies or surgeries, must be avoided through judicious application of evidence-based protocols and multidisciplinary input.

Recent Advances / Emerging Therapies

Recent advances in artificial intelligence (AI) and machine learning have begun to transform the detection and risk assessment of IFs, offering potential improvements in sensitivity, specificity, and workflow efficiency. Automated lesion characterization, risk prediction algorithms, and integrated clinical decision support tools are emerging to assist radiologists and clinicians. Molecular imaging and radiogenomics hold promise for personalized risk stratification, particularly in oncology surveillance. Ongoing research into the natural history of common IFs, such as adrenal nodules or thyroid incidentalomas, is refining management pathways and reducing unnecessary interventions.

Guideline Recommendations

Numerous professional bodies have issued guidelines for the management of IFs, including the American College of Radiology (ACR), European Society of Radiology, and organ-specific societies. Key recommendations emphasize stratification based on lesion characteristics, patient risk profile, and the use of standardized reporting systems (e.g., LI-RADS, Lung-RADS, Bosniak classification). Guidelines advocate for minimizing repeated imaging unless clinically indicated, utilizing decision aids, and engaging in shared decision-making. Regular updating of protocols to reflect evolving evidence is essential, as is interdisciplinary collaboration to ensure consistent, high-quality care.

Conclusion

The risk assessment of clinically relevant incidental findings across repeated imaging pathways is a complex, evolving challenge for modern medicine. It demands an evidence-based, patient-centered approach that balances the benefits of early detection with the risks of overdiagnosis. Advances in imaging technology, data analytics, and guideline development are enhancing clinician's ability to stratify risk and make informed decisions. Ongoing education, multidisciplinary collaboration, and adherence to best practice recommendations will be pivotal in optimizing outcomes for patients exposed to repeated imaging investigations.